THUNDERCOMM
15.3.2023 04:57:35 CET | Business Wire | Press release
Thundercomm, a world leading IoT product and solution provider, announces the release of new offerings in its smart IoT module portfolio to lower the barriers to enter the market and accelerate innovation in various AIoT industry segments, including robotics, handheld devices, tablets and smart cameras.
TurboX C2210 SOM is powered by the Qualcomm® QRB2210 System-on-Chip (SoC). It's designed with an optimized Linux operating system, discrete memory for more memory options to save the cost, and system fast boot, supports 1080P@30FPS video decode and a long life cycle to 2028, aiming to bring advanced features to entry-level devices with better performance and improved power consumption. The TurboX C2210 SOM supports the Linux system and can be applied to a variety of products like entry-tier robotics, e-scooter, smart home dock, smart camera and rugged handheld, etc.
TurboX C4210 SOM is powered by the Qualcomm® QRB4210 SoC. It features triple ISPs for advanced dual-camera experience, dedicated Compute DSP for computer vision and video post-processing. It's designed to support advanced graphics, bringing high value features to mid-tier devices. It's an ideal platform for both industrial and consumer applications requiring high data rates multimedia function, and can be applied to a broad range of devices including robotics, dash camera, video conference, smart retail, etc.
TurboX C5430 SOM integrates the Qualcomm® QCS5430 SoC, a 6nm processor with superior performance, power efficiency, premium connectivity, and 3.5 TOPS computing power. It supports 4K@30FPS video decode and 4K@30FPS video encode, Wi-Fi 6E, long range bluetooth, four MIPI CSIs, as well as a rich set of peripheral interfaces. The C5430 SOM is a high performance AIoT SOM for building handheld devices, industrial robots, service robots, Edge Box, providing customers with hardware interfaces and software SDK to validate functions and build the prototype quickly.
“Robotics industry is growing faster than ever as technology continuously advances in 5G, computing power and AI. Today, we see robots in almost every aspect of our lives, helping us do much more than we can do alone. Our newly released C2210 SOM and C4210 SOM will unlock the potential of more innovations in robotics, lowering the barriers for brands to enter and compete efficiently in this growing market,” said Pier Zhang, Director of Product Marketing at Thundercomm. “We are offering not only the hardware SOM and dev kits, but also the robot brain, software solutions to help customers build future-proof robot products faster and cost-effectively.”
“We congratulate Thundercomm on the launch of their industry leading SOMs. Recognizing the innovation of these new products, Qualcomm Technologies recently announced Qualcomm® Robotics RB1 and RB2 Development Kits are based on TurboX C2210 and C4210 respectively,” said Dev Singh, vice president, business development, and head of building, enterprise and industrial automation, Qualcomm Technologies, Inc. “Boosting a suite of complete robotics capabilities, including pre-integrated sensors from TDK, cameras, and AI SDKs, our development kits will enable developers to more easily prototype everyday robotics applications thus helping push the IoT ecosystem forward.”
The Qualcomm Robotics RB1 and RB2 Development Kit and SOMs of TurboX C2210, C4210, C5430 are available now for evaluation and testing.
About Thundercomm
Thundercomm, a joint venture between Thunder Software Technology Co., Ltd and Qualcomm (China) Holding Co. Ltd., a subsidiary of Qualcomm Technologies, Inc., was established to accelerate innovation in the Internet of Things and automotive industry, providing one-stop solutions powered by Qualcomm Technologies. Through its capabilities in operating systems including Android, Linux, and others, abroad software and on-device AI technology portfolio, and a global sales and support network, Thundercomm is a valuable and trusted partner to global customers aiming to build high-quality, next-generation products and shorten time-to-commercialization. Learn more at www.thundercomm.com
Qualcomm branded products are products of Qualcomm Technologies, Inc. and/or its subsidiaries. Qualcomm patented technologies are licensed by Qualcomm Incorporated.
Qualcomm is a trademark or registered trademark of Qualcomm Incorporated.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230314006083/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release
Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 10:00:00 CEST | Press release
Analyses from the multinational MILOS study show that LDL-C reductions achieved with up to one year of treatment with bempedoic acid-containing therapies translate to a 17.1% relative reduction and a 4.8% absolute reduction in predicted 10-year cardiovascular risk.1 Real-world data demonstrated clinically relevant mean LDL-C reductions of at least 24.9%, regardless of patient gender or glycaemic status, after one year of follow-up.2,3 Findings presented at ESC Congress 2026 reinforce the clinical value of bempedoic acid in routine clinical practice, and demonstrate the continued investment of Daiichi Sankyo in addressing outstanding unmet needs in cardiovascular disease (CVD). Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich,
TVS Motor Company Appoints Peyman Kargar as Director and Chief Executive Officer28.8.2026 09:31:00 CEST | Press release
Peyman Kargar appointed Director and Chief Executive Officer of TVS Motor Company, effective January 27, 2027 K. N. Radhakrishnan to continue as Director and Chief Executive Officer until then and subsequently will serve as Non-Executive Director up to the date of the ensuing AGM scheduled in July 2027 Appointment supports TVS Motor Company's next phase of growth and innovation TVS Motor Company, part of TVS VENU and a leading global manufacturer of two and three-wheelers, today announced the appointment of Peyman Kargar as Director and Chief Executive Officer, effective January 27, 2027. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260827012301/en/ Peyman Kargar Peyman will succeed K. N. Radhakrishnan, who will continue in his role until then to ensure a seamless transition. Following the transition, Radhakrishnan will serve as Non-Executive Director up to the date of the ensuing AGM scheduled in July 2027. He has been a
Philips and Imricor Launch Cardiac Interventional MR Lab Solution, Expanding Longstanding Collaboration27.8.2026 21:27:00 CEST | Press release
Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and Imricor Medical Systems (ASX: IMR), a pioneer and world-leading developer of MR-compatible products for interventional MR procedures, today announced a new Interventional MR (iMR) lab solution for Philips 1.5T MR. The first commercially available configuration* combines Philips’ 1.5T MRI platform and Imricor's portfolio of iMR systems and consumables, enabling an MR-guided workflow for cardiac intervention, without compromising on MR field strength. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260827693715/en/ Meeting the need for greater tissue insight during cardiac intervention Cardiac arrhythmias affect millions of people worldwide, and catheter ablation is an established and increasingly utilized treatment for many complex cardiac arrhythmias. Yet today, these procedures continue to rely primarily on X-ray fluoroscopy, which provides only
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom